Header Image

Learn more about QBECO SSI new treatment and how to enroll in the clinical trial at our upcoming events for patients. Health care professionals are also welcome to attend!

Join the Canadian Digestive Health Foundation, Qu Biologics and Dr. Shirin Kalyan Thursday August 23rd. 

Where: Palermo Medical Centre - 2525 Old Bronte Rd, Oakville, ON Suite 300

When: 7:00pm - 8:00pm (Please arrive 15 minutes early!)

Thursday August 23rd, 2018 

Light refreshments will be provided. 

More about the event:

The standard of care for IBD is based on symptom management by aggressive immune suppression, which has serious consequent risks. Furthermore, this approach has not changed the progression of disease for most patients living with IBD. Qu Biologics, a Canadian clinical stage biotechnology company founded by Dr. Hal Gunn, believes that the immune system can be retrained to become more resilient using a novel “bugs as drugs” approach. This hypothesis is currently being tested in Qu’s second Phase 2 trial in Crohn’s disease to determine time to mucosal healing. Dr. Shirin Kalyan, a translational immunologist with a doctorate in experimental medicine, will be presenting the current state of affairs in IBD management and how Qu is working to transform this paradigm to instead aim to restore health in patients. She will briefly cover the science behind Qu’s immunotherapy approach and the clinical experience to date. There will be plenty of time for questions and discussion.

About our speaker:

Dr. Shirin Kalyan is a translational immunologist and leads Qu Biologics’ Scientific Innovation. She earned her doctorate in Experimental Medicine and is a Faculty member in the Department of Medicine with the University of British Columbia. Dr. Kalyan has been studying the pathophysiology of disease rooted in immune dysfunction and metabolic disturbances for over 18 years. She was awarded the prestigious Humboldt fellowship to conduct research in Germany – to investigate how commonly used drugs affect the immune function in people and to harness the healing potential of the innate immune system for immunotherapy.

What's an SSI? Qu Biologics CEO Dr. Hal Gunn talks about QBECO SSI.

Learn more and take the questionnaire: www.restoretrial.ca
Footer Image